News:

Feb 10, 2020

Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)

Feb 03, 2020

Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections

Jan 30, 2020

Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China

See all news

Inovio is where
IMMUNO-INGENUITY is making the difference for patients with cancer and infectious diseases.

Learn more about our company

“At Inovio, the revolutionary power of our technology is superseded only by the dedication, passion, and expertise of the team we have brought together to bring our technology to life for patients in need.”

J. Joseph Kim, Ph.D.

President and CEO

Meet our team

Investor information

Review Inovio’s investor presentation highlighting our science, progress, and key upcoming milestones.

Download presentation

Inovio is focusing on transforming the prevention and treatment of cancer and infectious diseases.

Learn more about our focus

Inovio's technology is IMMUNO-INGENUITY in action

Inovio's activation immunotherapy platform is generating best-in-class immune responses in the fight against cancer and infectious diseases.

Explore our technology